Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
about
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchKnowledge on osteoporosis of prescriber according to level of medical instituteChallenges in implementing and maintaining osteoporosis therapy.Intravenous Zoledronate for a Patient with Paget's Disease.Treatment for Osteoporosis among Women in Japan: Associations with Patient Characteristics and Patient-Reported Outcomes in the 2008-2011 Japan National Health and Wellness SurveysThe relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients.If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Measuring and improving adherence to osteoporosis pharmacotherapy.Structural equation modeling of the proximal-distal continuum of adherence drivers.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?Which Bisphosphonate? It's the Compliance!: Decision Analysis.Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study.Antiresorptive therapies for osteoporosis: a clinical overview.Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.Bisphosphonate use and subsequent hip fracture in South Korea.A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men.Considerations regarding adherence of anti-osteoporosis therapy.Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy.Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research GroupImpact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.Incidence of second hip fracture and compliant use of bisphosphonate.Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.Understanding patient compliance and persistence with osteoporosis therapy.Persistence with intravenous zoledronate in elderly patients with osteoporosis.
P2860
Q26782621-A503DC05-34D1-4EA7-8A20-8DF2BE5CD274Q33822430-F38E820D-66D3-4CC4-9DFD-AA5EC81D11B6Q34073740-09343B22-4489-4D05-A341-B997614FA981Q34219216-F069BC87-FDC3-4474-A5D8-8AA91321DEF0Q34837665-16C2C4BE-EF8A-4017-9473-1E2118BA81AAQ34978740-EBB13CF2-1C9A-47C0-B588-47558AB3AB71Q35050249-8C60B5C8-3230-4EFA-A1B6-890B887B8AEAQ35177690-268E03CF-927C-459D-A810-67C657E74628Q36429615-68F1CA4C-E8CD-40DB-95B0-BA770274F864Q36897441-86F7D2AE-04AD-4880-B739-D882D22C88F4Q36989616-F4869F20-9553-4B82-AC27-5D19F6B0FD39Q36989633-9ADC058B-DF24-4890-9D7C-6357C243F877Q37402282-B8B7EBE5-69A4-4D4A-8D17-3CA94005D4E6Q37422363-4C6115A8-5EC2-4F6F-B934-FEA3E7BFD818Q37926914-345B5FE8-193B-434D-967A-EA09E6E6FAD8Q38107182-7C9CADBC-BA74-411F-82B6-AFB0BCD4ED3AQ38107388-D4DD80A8-E690-47FF-8925-3456A05D83E2Q38183263-ED5638D6-8D00-4AFA-A82D-36C720CB7350Q38294766-F40C7058-0C75-4F07-918E-55440E8DFB32Q38731473-D69D99DE-F146-4A32-B815-B15594F8DCFCQ39874235-C1F8F29C-ECCC-419F-81FE-F51579C7F243Q41039515-C1209AEC-350D-43BB-8C2B-E4CC1B0AC0A7Q43038610-BE254BEE-5E61-469E-AF0A-A364539ECF6BQ45327686-0C9CAB83-D270-4173-ACCD-7781AE376145Q48701601-D85DE58A-69BF-4BCC-8046-6DA6A2585208Q50629816-FD70873A-AE8A-43C5-A897-5333899DBA11Q51174767-087F0A95-0812-4324-9469-00146DA54E26
P2860
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Factors affecting long-term co ...... : alendronate and risedronate.
@en
Factors affecting long-term co ...... : alendronate and risedronate.
@nl
type
label
Factors affecting long-term co ...... : alendronate and risedronate.
@en
Factors affecting long-term co ...... : alendronate and risedronate.
@nl
prefLabel
Factors affecting long-term co ...... : alendronate and risedronate.
@en
Factors affecting long-term co ...... : alendronate and risedronate.
@nl
P2093
P2860
P1476
Factors affecting long-term co ...... : alendronate and risedronate.
@en
P2093
Eri Akasaka
Kae Yanagimoto
Kazumi Sakota
Masayuki Kamatari
Nobuhiro Ozawa
Shiro Koto
Yumiko Suzuki
P2860
P2888
P304
P356
10.1007/S00774-007-0768-6
P577
2007-08-25T00:00:00Z